alpha-1 adrenergic receptor antagonist; prostate-selective alpha blocker

From Aaushi
Jump to navigation Jump to search

Indications

* use for treating hypertension declined after the ALLHAT study

Adverse effects

* not associated with increased risk of cardiovascular events in contrast to findings of ALLHAT study[5]

More general terms

More specific terms

Additional terms

References

  1. Prescriber's Letter 10(9):53 2003
  2. Prescriber's Letter 17(4): 2010 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260402&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 Deprecated Reference
  4. 4.0 4.1 4.2 Welk B et al The risk of fall and fracture with the initiation of a prostate- selective alpha antagonist: a population based cohort study. BMJ 2015;351:h5398 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26502947 <Internet> http://www.bmj.com/content/351/bmj.h5398
  5. 5.0 5.1 5.2 5.3 Hundemer GL, Knoll GA, Petrcich W et al. Kidney, cardiac, and safety outcomes associated with alpha-blockers in patients with CKD: A population-based cohort study. Am J Kidney Dis 2021 Feb; 77:178. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32920153 https://www.ajkd.org/article/S0272-6386(20)30937-9/fulltext